10 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27839686	65	Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.	Merck Research Laboratories
27017115	77	Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.	Merck Research Laboratories
26191360	99	Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.	Merck Research Laboratories
25017033	148	Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold.	University of Kansas Specialized Chemistry Center
24075732	43	Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.	Merck Research Laboratories
24900480	75	Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.	TBA
28753313	45	Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid)	Sage Therapeutics
28530802	121	Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.	Vanderbilt University Institute of Imaging Science
28431879	123	Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.	Merck